
Cardiff Lexington Corp
93
Recent news coverage includes sector-related updates and a past report on company restructuring and leadership changes in June 2024.
- Cardiff Lexington restructured accounting and changed leadership as reported in June 2024 [N2].
- Recent news primarily covers agricultural commodity markets and unrelated sector developments, with no direct operational updates for Cardiff Lexington Corp [N1][N2][N3][N4][N5][N6][N7][N8].
Cardiff Lexington Corp is a targeted healthcare holding company that acquires and builds middle-market niche healthcare clinics, primarily in orthopedics, spine care, and pain management. The company operates through subsidiaries including Nova Ortho and Spine, LLC, which provides specialty care to traumatic injury victims, focusing on plaintiff-related care and uninsured patients in Florida and Georgia. It also owns Edge View Properties, a real estate company holding residential and agricultural land in Idaho. The company employs a geographic-specific acquisition strategy across three pillars: core cash flow from physician practices, asset acquisition of healthcare real estate, and finance through managing personal injury practice accounts receivable. Acquisitions become wholly owned subsidiaries with management retained or replaced to optimize operations. The business model involves extended accounts receivable collection cycles of 12 to 24 months due to payment timing linked to legal settlements, which creates liquidity and credit risks. The company has sustained operating losses and an accumulated deficit, with liquidity ratios below 1 as of September 30, 2026. Management plans to fund operations through working capital and additional financing.
Cardiff Lexington Corp is a healthcare holding company focused on acquiring and managing niche orthopedic and related specialty clinics primarily in Florida and Georgia. Its business model centers on plaintiff-related care with extended accounts receivable cycles tied to legal settlements, creating liquidity and credit risks. The company also owns real estate assets through a subsidiary. Financial disclosures as of September 30, 2026, show revenue of $1.9 million and a net loss of $3.2 million, with liquidity ratios indicating current liabilities exceed current assets. The company has a history of operating losses and an accumulated deficit, with management noting substantial doubt about going concern but planning to fund operations through working capital and financing. Recent news coverage is largely sector-focused with no direct operational updates since mid-2024. Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company’s acquisition and value creation strategy targets niche healthcare clinics with strong organic growth potential and recurring revenue streams. Its management team's industry experience and relationships may facilitate identifying and integrating attractive acquisition targets. The ownership of real estate assets provides diversification and potential long-term value. If operational efficiencies improve and accounts receivable management strengthens, the company could enhance cash flow and profitability over time.
Cardiff Lexington faces significant risks from its extended accounts receivable collection cycle of 12 to 24 months, which strains liquidity and cash flow. The company has sustained operating losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern. Dependence on external financing to fund operations and acquisitions introduces dilution and restrictive covenants. Credit losses and operational inefficiencies related to receivables aging may further impair financial performance. The lack of systematic processes for receivables management and the complexity of plaintiff-related care payments add to operational challenges.
Cardiff Lexington's moat is based on its niche focus on middle-market orthopedic and related specialty healthcare clinics with a plaintiff-related care model that involves extended accounts receivable cycles tied to legal settlements. Its acquisition strategy targets undervalued and undercapitalized healthcare companies, leveraging management's industry relationships and operational expertise to optimize and grow acquired subsidiaries. The combination of healthcare service specialization, geographic focus, and integration of real estate assets provides some differentiation. However, the extended receivable collection period and reliance on legal settlements introduce operational and financial risks that may limit competitive advantages.
• Going Concern Uncertainty: The company has sustained operating losses and an accumulated deficit of approximately $79.5 million as of December 31, 2025, with negative cash flow from operations raising substantial doubt about its ability to continue as a going concern.
• Extended Accounts Receivable Collection Cycle: The business model involves plaintiff-related care with payment collection tied to legal settlements, resulting in accounts receivable cycles of 12 to 24 months, which creates liquidity constraints and increases credit risk exposure.
• Dependence on External Financing: To manage liquidity and fund acquisitions, the company relies on external financing sources, which may lead to increased interest expenses, dilution of equity, and restrictive covenants limiting operational flexibility.
• Operational Challenges in Receivables Management: The company lacks systematic processes and resources to manage aging accounts receivable, potentially leading to inefficiencies, higher operational costs, and financial metric distortions.
Business trends: Continued focus on acquiring and optimizing middle-market orthopedic and related healthcare clinics with a strategy emphasizing recurring revenue and real estate asset ownership.
Execution milestones: Integration of acquired subsidiaries, management restructuring, and efforts to improve accounts receivable management and liquidity.
Key risks: Extended accounts receivable collection cycles impacting cash flow, dependence on external financing, sustained operating losses, and going concern uncertainties.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Cardiff Lexington Corp is a targeted healthcare holding company focused on acquiring and building middle-market niche healthcare clinics primarily in orthopedics, spine care, and pain management.
- The company operates through subsidiaries including Nova Ortho and Spine, LLC, acquired in May 2021, which provides specialty and ancillary care services in Florida and Georgia focused on traumatic injury victims, plaintiff-related care, and uninsured patients.
- Cardiff Lexington also owns Edge View Properties, Inc., a real estate company owning residential and agricultural land in Idaho, with no current development plans.
- The company employs a geographic-specific acquisition strategy across three pillars: core cash flow from physician practices, asset acquisition of real estate such as ambulatory surgery centers, and finance through managing personal injury practice accounts receivable.
- Acquisitions become wholly owned subsidiaries with management either retained or replaced by suitable executives; the company aims to provide these entities with benefits of being publicly traded including access to capital markets.
- The business model involves extended accounts receivable collection cycles of 12 to 24 months due to plaintiff-related care payment timing tied to legal settlements.
- This extended collection cycle creates risks including liquidity and cash flow constraints, increased credit loss exposure, dependence on external financing, impact on financial metrics, and operational challenges.
- The company had an accumulated deficit of approximately $79.5 million as of December 31, 2025, with sustained operating losses and negative cash flow from operations raising substantial doubt about its ability to continue as a going concern.
- Management believes current working capital and expected financing should fund operations for at least one year, but additional financing of $5 to $10 million may be needed to execute the business plan.
- Financial snapshot as of September 30, 2026, shows current assets of $24.2 million, current liabilities of $28.5 million, resulting in a current ratio of 0.85 and a cash ratio of 0.02.
- Revenue for the nine months ended September 30, 2026, was approximately $1.9 million with a net loss of about $3.2 million and basic and diluted EPS of -$0.22 per share.
- The company restructured accounting and changed leadership as reported in June 2024.
- Recent news coverage includes general market and sector news but no direct operational updates for Cardiff Lexington Corp since mid-2024.
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Generated 2026-11-10
- Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
- S1 | 2026-03-10 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Corn Posting Slight Tuesday AM Gains Ahead of USDA Release | https://www.nasdaq.com/articles/corn-posting-slight-tuesday-am-gains-ahead-usda-release
- N2 | 2026-11-10 | www.nasdaq.com | JAKKS Pacific Signs Distribution Deal With Alliance Entertainment For Anime, VTuber Products | https://www.nasdaq.com/articles/jakks-pacific-signs-distribution-deal-alliance-entertainment-anime-vtuber-products
- N3 | 2026-11-10 | www.nasdaq.com | Waters' BD OneFlow Tests Clear FDA Review; U.S. Launch Set For Spring 2027 | https://www.nasdaq.com/articles/waters-bd-oneflow-tests-clear-fda-review-us-launch-set-spring-2027
- N4 | 2026-11-10 | www.nasdaq.com | Harvard Bioscience (HBIO) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/harvard-bioscience-hbio-q3-2026-earnings-call-transcript
- N5 | 2026-11-10 | www.nasdaq.com | Wheat Reverting from Monday Action with Slight Winter Wheat Gains to Start Tuesday | https://www.nasdaq.com/articles/wheat-reverting-monday-action-slight-winter-wheat-gains-start-tuesday
- N6 | 2026-11-10 | www.nasdaq.com | Ovid Therapeutics Reports Q3 Results; Multiple Pipeline Readouts Expected In 2027 | https://www.nasdaq.com/articles/ovid-therapeutics-reports-q3-results-multiple-pipeline-readouts-expected-2027
- N7 | 2026-11-10 | www.nasdaq.com | Hot CPI and Hawkish Fed Weigh on Stocks | https://www.nasdaq.com/articles/hot-cpi-and-hawkish-fed-weigh-stocks
- N8 | 2026-11-10 | www.nasdaq.com | Soybeans Showing Quiet Pre-USDA Report Trade | https://www.nasdaq.com/articles/soybeans-showing-quiet-pre-usda-report-trade
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


